arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Unicycive Therapeutics, Inc.

UNCY
$5.07 ▲ +0.04 (+0.70%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
26 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Unicycive Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $121.2M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -17.7%
FCF / Share $-0.26
Trailing P/E
Price / Book 3.4x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

26-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0%
Net Income Profit after all expenses
$-12.82M
↑ +12.6%
FCF / Share Free cash flow per share
$-0.26
↓ -242.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
10
Cash Quality
72

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters